These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11830752)

  • 1. Pharmacology of SCH00013: a novel Ca2+ sensitizer.
    Endoh M; Sugawara H; Mineshima M
    Cardiovasc Drug Rev; 2001; 19(4):345-66. PubMed ID: 11830752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 1st communication: phosphodiesterase III inhibitory effect and class III antiarrhythmic effect in guinea-pig heart.
    Hino M; Sugawara H; Yoshimura A; Ogura A; Yoshioka K; Sakato M; Endoh M
    Arzneimittelforschung; 1999 May; 49(5):398-406. PubMed ID: 10367101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 3rd communication: stereoselectivity of the enantiomers in cardiovascular effects.
    Sugawara H; Hino M; Yoshimura A; Yoshioka K; Sakato M; Endoh M
    Arzneimittelforschung; 1999 May; 49(5):412-9. PubMed ID: 10367103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel cardiotonic agent SCH00013 acts as a Ca++ sensitizer with no chronotropic activity in mammalian cardiac muscle.
    Sugawara H; Endoh M
    J Pharmacol Exp Ther; 1998 Oct; 287(1):214-22. PubMed ID: 9765340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 2nd communication: in vivo cardiovascular effects and bioavailability in dogs.
    Yoshimura A; Koide Y; Yoshioka K; Hino M; Sugawara H; Sakato M; Endoh M
    Arzneimittelforschung; 1999 May; 49(5):407-11. PubMed ID: 10367102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure.
    Hamabe L; Kawamura K; Kim SM; Yoshiyuki R; Fukayama T; Shimizu M; Fukushima R; Tanaka R
    J Pharmacol Sci; 2014; 124(3):386-93. PubMed ID: 24599141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SCH00013, a novel Ca(2+) sensitizer with positive inotropic and no chronotropic action in heart failure.
    Tadano N; Morimoto S; Yoshimura A; Miura M; Yoshioka K; Sakato M; Ohtsuki I; Miwa Y; Takahashi-Yanaga F; Sasaguri T
    J Pharmacol Sci; 2005 Jan; 97(1):53-60. PubMed ID: 15644593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan, a new inotropic and vasodilator agent.
    Toller WG; Stranz C
    Anesthesiology; 2006 Mar; 104(3):556-69. PubMed ID: 16508404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 4th communication: influence on experimentally induced ventricular arrhythmia in dogs.
    Yoshimura A; Yoshioka K; Hino M; Sugawara H; Sakato M; Endoh M
    Arzneimittelforschung; 1999 May; 49(5):420-6. PubMed ID: 10367104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in intracellular Ca2+ mobilization and Ca2+ sensitization as mechanisms of action of physiological interventions and inotropic agents in intact myocardial cells.
    Endoh M
    Jpn Heart J; 1998 Jan; 39(1):1-44. PubMed ID: 9601480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium.
    Uhlmann R; Schwinger RH; Lues I; Erdmann E
    Basic Res Cardiol; 1995; 90(5):365-71. PubMed ID: 8585857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs.
    Duncker DJ; Verdouw PD
    Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanism of action of Ca2+ sensitizers--update 2001.
    Endoh M
    Cardiovasc Drugs Ther; 2001 Sep; 15(5):397-403. PubMed ID: 11855658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac Ca2+ signaling and Ca2+ sensitizers.
    Endoh M
    Circ J; 2008 Dec; 72(12):1915-25. PubMed ID: 18981594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?
    Endoh M
    Br J Pharmacol; 2007 Apr; 150(7):826-8. PubMed ID: 17325657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan in regional myocardial ischemia.
    Pieske B
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):379-81. PubMed ID: 12656119
    [No Abstract]   [Full Text] [Related]  

  • 18. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers.
    Lues I; Beier N; Jonas R; Klockow M; Haeusler G
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):883-92. PubMed ID: 7687712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites.
    Asif M
    Mini Rev Med Chem; 2018; 18(16):1354-1362. PubMed ID: 27594341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition.
    Kaheinen P; Pollesello P; Hertelendi Z; Borbély A; Szilágyi S; Nissinen E; Haikala H; Papp Z
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):74-8. PubMed ID: 16433895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.